clinical trial · NCT04890509
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
BerGenBio ASA·phase2·completed·n = 115
COVID-19BemcentinibSoC
brief summary
The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).
started
Oct 20, 2020
primary completion
May 25, 2021
completion
May 25, 2021
last updated
Oct 16, 2024
official title
A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol